Shandong Xinhua Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Shandong Xinhua Pharmaceutical has been growing earnings at an average annual rate of 11.1%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 8.2% per year. Shandong Xinhua Pharmaceutical's return on equity is 8.8%, and it has net margins of 5%.
Key information
11.1%
Earnings growth rate
10.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 8.2% |
| Return on equity | 8.8% |
| Net Margin | 5.0% |
| Next Earnings Update | 24 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shandong Xinhua Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 7,073 | 357 | 980 | 352 |
| 30 Jun 22 | 6,673 | 343 | 900 | 340 |
| 31 Mar 22 | 6,623 | 357 | 908 | 343 |
| 31 Dec 21 | 6,560 | 349 | 931 | 341 |
| 30 Sep 21 | 6,307 | 364 | 935 | 338 |
| 30 Jun 21 | 6,271 | 353 | 992 | 311 |
| 31 Mar 21 | 6,068 | 339 | 957 | 301 |
| 31 Dec 20 | 6,006 | 325 | 944 | 298 |
| 30 Sep 20 | 5,814 | 305 | 982 | 261 |
| 30 Jun 20 | 5,769 | 323 | 990 | 260 |
| 31 Mar 20 | 5,682 | 310 | 1,049 | 253 |
| 31 Dec 19 | 5,606 | 300 | 1,105 | 235 |
| 30 Sep 19 | 5,716 | 303 | 1,107 | 229 |
| 30 Jun 19 | 5,680 | 281 | 1,072 | 233 |
| 31 Mar 19 | 5,457 | 264 | 1,012 | 201 |
| 31 Dec 18 | 5,245 | 255 | 924 | 187 |
| 30 Sep 18 | 5,023 | 229 | 859 | 172 |
| 30 Jun 18 | 4,800 | 226 | 809 | 151 |
| 31 Mar 18 | 4,638 | 226 | 710 | 204 |
| 31 Dec 17 | 4,516 | 210 | 725 | 161 |
| 30 Sep 17 | 4,491 | 207 | 718 | 130 |
| 30 Jun 17 | 4,420 | 183 | 762 | 97 |
| 31 Mar 17 | 4,306 | 154 | 799 | 0 |
| 31 Dec 16 | 4,015 | 122 | 724 | 0 |
| 30 Sep 16 | 3,800 | 110 | 667 | 0 |
| 30 Jun 16 | 3,647 | 103 | 624 | 0 |
| 31 Mar 16 | 3,602 | 89 | 611 | 0 |
Quality Earnings: SHNX.Y has a large one-off gain of CN¥82.3M impacting its last 12 months of financial results to 30th September, 2022.
Growing Profit Margin: SHNX.Y's current net profit margins (5%) are lower than last year (5.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHNX.Y's earnings have grown by 11.1% per year over the past 5 years.
Accelerating Growth: SHNX.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SHNX.Y had negative earnings growth (-2.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-17.3%).
Return on Equity
High ROE: SHNX.Y's Return on Equity (8.8%) is considered low.